Table 3.
ROC curve analysis of clinicopathological data.
| Parameter | AUC | 95% CI | p value | |
|---|---|---|---|---|
| Lower bound | Upper bound | |||
| Nipple discharge | ||||
| CA153 (U/mL) | 0.784 | 0.719 | 0.849 | <0.01 |
| TSGF (U/mL) | 0.764 | 0.697 | 0.842 | <0.01 |
| CA125 (U/mL) | 0.780 | 0.713 | 0.846 | <0.01 |
| CEA (ng/mL) | 0.779 | 0.712 | 0.846 | <0.01 |
| Combination ND | 0.827 | 0.769 | 0.885 | <0.01 |
| Serum | ||||
| CA153 (U/mL) | 0.762 | 0.692 | 0.832 | <0.01 |
| TSGF (U/mL) | 0.770 | 0.701 | 0.839 | <0.01 |
| CA125 (U/mL) | 0.732 | 0.659 | 0.804 | <0.01 |
| CEA (ng/mL) | 0.712 | 0.639 | 0.786 | <0.01 |
| Combination ND + Serum | 0.863 | 0.814 | 0.913 | <0.01 |
CA15-3: cancer antigen 15-3; CEA: carcinoembryonic antigen; CA-125: cancer antigen 125; TSGF: malignant tumor-specific growth factor; ROC: receiver operating characteristic; AUC: area under the curve; CI: confidence interval; ND: nipple discharge.